Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:1863–9. https://doi.org/10.1016/j.bbmt.2015.07.032.

Article  PubMed  PubMed Central  Google Scholar 

Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Prim. 2023;9:27. https://doi.org/10.1038/s41572-023-00438-1.

Article  PubMed  Google Scholar 

Ramachandran V, Kolli SS, Strowd LC. Review of graft-versus-host disease. Dermatol Clin. 2019;37:569–82. https://doi.org/10.1016/j.det.2019.05.014.

Article  CAS  PubMed  Google Scholar 

Jacobson P, Uberti J, Davis W, Ratanatharathorn V. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant. 1998;22:217–25. https://doi.org/10.1038/sj.bmt.1701331.

Article  CAS  PubMed  Google Scholar 

Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, et al. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000;6:190–7. https://doi.org/10.1016/s1083-8791(00)70042-5.

Article  CAS  PubMed  Google Scholar 

Mori T, Aisa Y, Nakazato T, Yamazaki R, Shimizu T, Mihara A, et al. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies. Transplant Proc. 2007;39:1615–9. https://doi.org/10.1016/j.transproceed.2006.12.042.

Article  CAS  PubMed  Google Scholar 

Capron A, Mourad M, De Meyer M, De Pauw L, Eddour DC, Latinne D, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010;11:703–14. https://doi.org/10.2217/pgs.10.43.

Article  CAS  PubMed  Google Scholar 

Zuo X, Ng CM, Barrett JS, Luo A, Zhang B, Deng C, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genom. 2013;23:251–61. https://doi.org/10.1097/FPC.0b013e32835fcbb6.

Article  CAS  Google Scholar 

Campagne O, Mager DE, Brazeau D, Venuto RC, Tornatore KM. Tacrolimus population pharmacokinetics and multiple CYP3A5 genotypes in black and white renal transplant recipients. J Clin Pharmacol. 2018;58:1184–95. https://doi.org/10.1002/jcph.1118.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu J, Patel T, Miller JA, Torrice CD, Aggarwal M, Sketch MR, et al. Influence of germline genetics on tacrolimus pharmacokinetics and pharmacodynamics in allogeneic hematopoietic stem cell transplant patients. Int J Mol Sci. 2020;21:858. https://doi.org/10.3390/ijms21030858.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seligson ND, Zhang X, Zemanek MC, Johnson JA, VanGundy Z, Wang D, et al. CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation. Front Pharmacol. 2023;14:1334440. https://doi.org/10.3389/fphar.2023.1334440.

Article  CAS  PubMed  Google Scholar 

Ram R, Storer B, Mielcarek M, Sandmaier BM, Maloney DG, Martin PJ, et al. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:414–22. https://doi.org/10.1016/j.bbmt.2011.08.016.

Article  CAS  PubMed  Google Scholar 

Ganetsky A, Shah A, Miano TA, Hwang WT, He J, Loren AW, et al. Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:568–72. https://doi.org/10.1038/bmt.2015.323.

Article  CAS  PubMed  Google Scholar 

Hagen PA, Adams W, Smith S, Tsai S, Stiff P. Low mean post-transplantation tacrolimus levels in weeks 2–3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. Bone Marrow Transplant. 2019;54:155–8. https://doi.org/10.1038/s41409-018-0267-5.

Article  CAS  PubMed  Google Scholar 

Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson DM, et al. Effect of early post-transplantation tacrolimus concentration on the risk of acute graft-versus-host disease in allogenic stem cell transplantation. Cancers (Basel). 2021;13:613. https://doi.org/10.3390/cancers13040613.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morishita T, Okabe M, Kawaguchi Y, Lee Y, Ohbiki M, Osaki M, et al. Higher peak tacrolimus concentrations after allogeneic hematopoietic stem cell transplantation increase the risk of endothelial cell damage complications. Biol Blood Marrow Transplant. 2018;24:2509–16. https://doi.org/10.1016/j.bbmt.2018.07.029.

Article  CAS  PubMed  Google Scholar 

Abramson MH, Gutgarts V, Zheng J, Maloy MA, Ruiz JD, Scordo M, et al. Acute kidney injury in the modern era of allogeneic hematopoietic stem cell transplantation. Clin J Am Soc Nephrol. 2021;16:1318–27. https://doi.org/10.2215/CJN.19801220.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao JM, Yang D, Clark MC, Otoukesh S, Cao T, Ali H, et al. Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Bone Marrow Transplant. 2022;57:232–42. https://doi.org/10.1038/s41409-021-01528-y.

Article  CAS  PubMed  Google Scholar 

Mori T, Kato J, Shimizu T, Aisa Y, Nakazato T, Yamane A, et al. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors. Biol Blood Marrow Transplant. 2012;18:229–34. https://doi.org/10.1016/j.bbmt.2011.06.008.

Article  CAS  PubMed  Google Scholar 

Prograf (tacrolimus) [package insert]. Northbrook, IL: Astellas Pharma US, Inc.; 2023.

Zhu J, Campagne O, Torrice CD, Flynn G, Miller JA, Patel T, et al. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients. Clin Transl Sci. 2021;14:908–18. https://doi.org/10.1111/cts.12956.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maynard RD, Bates P, Korpi-Steiner N. Monitoring tacrolimus toxicity following Paxlovid administration in a liver transplant patient. Pract Lab Med. 2023;36: e00322. https://doi.org/10.1016/j.plabm.2023.e00322.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98:19–24. https://doi.org/10.1002/cpt.113.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19:215–23. https://doi.org/10.1038/gim.2016.87.

Article  PubMed  Google Scholar 

R Core Team R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2023. https://www.R-project.org/. Cited 5 Nov 2024.

Sanghavi K, Ribbing J, Rogers JA, Ahmed MA, Karlsson MO, Holford N, et al. Covariate modeling in pharmacometrics: general points for consideration. CPT Pharmacomet Syst Pharmacol. 2024;13:710–28. https://doi.org/10.1002/psp4.13115.

Article  CAS  Google Scholar 

Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant. 2001;28:753–8. https://doi.org/10.1038/sj.bmt.1703224.

Article  CAS  PubMed  Google Scholar 

Elens L, Hesselink DA, Bouamar R, Budde K, de Fijter JW, De Meyer M, et al. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Ther Drug Monit. 2014;36:71–9. https://doi.org/10.1097/FTD.0b013e31829da6dd.

Article